Induced pluripotent stem cells (iPSCs) were first generated by Yamanaka and colleagues
over a decade ago. Since then, iPSCs have been successfully differentiated into many …

Morbidity and mortality from ischaemic heart disease (IHD) and heart failure (HF) remain
significant in Europe and are increasing worldwide. Patients with IHD or HF might benefit …

Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CM) have been
intensively used in drug development and disease modeling. Since iPSC-cardiomyocyte …

Marine demosponges of the Verongiida order are considered a gold-mine for bioinspired
materials science and marine pharmacology. The aim of this work was to simultaneously …

Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) are promising
candidates to treat myocardial infarction and other cardiac diseases. Such treatments …

Advances in stem cell technologies, revolutionizing regenerative therapies and advanced in
vitro testing, require novel cell manufacturing pipelines able to cope with scale up and …

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have the
potential to remuscularize infarcted hearts but their arrhythmogenicity remains an obstacle to …

Duchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene. Previously,
we showed that adenine base editing (ABE) can efficiently correct a nonsense point …

Myocardial infarction (MI) remains one of the leading cause of mortality over the world.
However, current treatments are more palliative than curative, which only stall the …

Cardiovascular diseases represent the major cause of morbidity and mortality worldwide.
Multiple studies have been conducted so far in order to develop treatments able to prevent …